Expanding Access to Untested Peptides Raises Patient Safety Concerns

WASHINGTON, D.C. (October 28, 2026) In response to today's announcement by the U.S. Department of Health and Human Services (HHS) allowing the temporary compounding of certain peptides lacking FDA approval, the Partnership to Fight Chronic Disease (PFCD) issued the following statement:

“For millions of Americans managing one or more chronic conditions, access to safe, effective treatments is essential to maintaining their health and quality of life.  Medical innovation offers tremendous promise, but expanding access to products without adequate evidence of their safety, quality, and effectiveness can expose patients to unnecessary and poorly understood risks.

“People living with chronic conditions often face complex treatment regimens, multiple medications, and heightened vulnerability to adverse effects or drug interactions. The potential for dangerous interactions among FDA-approved prescription medicines and unregulated compounded products puts patients at significant risk. Expanding access to unproven products without sufficient clinical evidence raises serious concerns and in no way confirms that broader availability means a product has been deemed safe and effective.

“PFCD urges HHS and FDA to maintain rigorous, science-based safeguards, transparent patient information, and meaningful oversight. Americans deserve access to promising innovations, but not if it compromises the confidence that the treatments they receive have been appropriately evaluated and will not put their health at greater risk. Expanding access should never come at the expense of patient safety or public confidence in the treatments on which Americans rely.”

###